SequelSEC

Caribou Biosciences, Inc. CRBU

Biological Products, (No Diagnostic Substances) · CIK 0001619856 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$10.04M
Fiscal year ended 2026-06-30
Operating income
-$109.47M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$112.50MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$1.16Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue10.1×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity0.9×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Biological Products, (No Diagnostic Substances) filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
CapEx / revenue12.2%75th
SBC / revenue113.6%70th
FCF margin-1006.8%31th
Net margin-1327.4%33th
Operating margin-1329.4%34th
R&D / revenue980.7%66th
Current ratio5.71x58th
Revenue YoY growth11.7%54th

Caribou Biosciences, Inc. (CRBU) reported revenue of $10.04M and net income of -$103.40M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Caribou Biosciences, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Caribou Biosciences, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$10.04M
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$109.47M
Net income-$103.40M
Research & development$85.77M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$33.74M
Selling & marketingUnavailable

Balance

Caribou Biosciences, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$26.19M
Total assets$142.77M
Current assets$116.60M
Total liabilities$44.67M
Current liabilities$17.97M
Total equity incl. NCI$98.10M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivable$203.00K
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$3.08M

Cash flow

Caribou Biosciences, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$95.78M
Capital expenditures-$28.00K
Investing cash flow$71.75M
Financing cash flow$24.98M
Net change in cash$947.00K
Stock-based compensation$10.50M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$2.59M

Derived

Caribou Biosciences, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flowUnavailable
Gross marginUnavailable
Operating margin-1090.9%
FCF marginUnavailable
SBC / revenue104.7%
Current ratio6.49x
Revenue YoY growth10.0%
Net margin-1030.4%
R&D / revenue854.7%
CapEx / revenue-0.3%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open CRBU in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-03-05View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.